Skip to main content
Premium Trial:

Request an Annual Quote

King's Health Partners Implements IDBS Translational Medicine Platform for Cancer Research

Premium

IDBS said this week that King's Health Partners has deployed its Oncology Research Information System to manage breast cancer data from multiple sites.

According to IDBS, the platform will allow KHP to combine clinical, genetic, and tissue sample data from more than 26,000 breast cancer patients as well as incorporate data from newly consented patients.

Peter Parker, who heads the cancer studies division and is also the research and development lead for the Integrated Cancer Center at KHP, said that the platform will help the hospital "better understand the complex causes and molecular basis of cancer" by enabling clinicians to make "better use of patient data."

IDBS' ORIS is an informatics platform for examining clinical, diagnostic, pathological, biopsy, research, and genomics data. It pulls in information from multiple sources including an internal cancer information system, electronic patient records, diagnostic imaging, and breast pathology data.

The platform also includes disease ontologies and terminology mapping, which support clinical data standards including ICD-10. All patient data is de-identified in the secure system and made available to genomic analysis applications for patient outcomes and clustering.

ORIS can also be used by pharmaceutical, biotechnology, and diagnostic companies looking to form research collaborations focused on cancer. It can be used to identify patient cohorts — based on similar disease characteristics — whose treatment, genetic profiles, and outcomes can be followed.

ORIS is part of a larger nine-year partnership between IDBS and KHP announced last year that aims to use patients' genomic and clinical profiles to develop individualized cancer therapies (BI 03/11/2011).

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.